

Pipeline

Asset	Indication	Preclinical	Phase 1	Phase 2	Phase 3
FB102	Graft vs Host Disease				
	Vitiligo				
	Alopecia Aerata				

FB-102

- CD122 is subunit of IL-2/IL-15 receptors which are key regulators of NK cells and T cell subsets
- FB-102 (Forte's anti-CD122 antibody) is designed to mediate NK and CD 8+ T cells specifically
- Significant amount of proof-of-concept preclinical data supports activity of CD-122 blockade, including in GvHD and vitiligo

[HOME](#)[ABOUT US](#)[MANAGEMENT](#)[PIPELINE](#)[NEWS](#)[INVESTOR RELATIONS](#)[CONTACT US](#)

HEADQUARTERS

 Forte Biosciences, Inc.
3060 Pegasus Park Dr.
Building 6
Dallas, TX 75247

 inquiry@fortebiorx.com

EMAIL ALERTS

☐ Press Releases☐ Presentations☐ End of Day Stock Quote☐ Events☐ SEC Filings